Name & Company Information Location Interests Events
user-icon

Samuel Aballéa

Creativ-Ceutical

VP HEOR

Paris

France

Health Economics, Health Technology Assessment, Methods, Modeling, Outcome Assessment, Patient Preference & Adherence, Real World Data W10: TREATMENT PATTERNS USING ADMINISTRATIVE CLAIMS DATA: GUIDING PRINCIPLES FOR IMPERFECT DATA
user-icon

Kenji Adachi

Amgen Astellas BioPharma K.K.

Head

Chiyoda-ku, Tokyo

Japan

W10: TREATMENT PATTERNS USING ADMINISTRATIVE CLAIMS DATA: GUIDING PRINCIPLES FOR IMPERFECT DATA
Jeonghoon_Ahn

Jeonghoon Ahn

Ewha Womans University

Associate Professor

Seoul

Korea, Republic of

-
Jeonghoon_Ahn

Jeonghoon Ahn

Ewha Womans University

Associate Professor

Seoul

Korea, Republic of

Health Economics, Health Technology Assessment, Methods, Modeling Network Meta-Analysis and Indirect Treatment Comparisons, IP14: MANAGED ENTRY SCHEMES: HYPE VS. REALITY, EDUCATIONAL SYMPOSIUM: CHALLENGES AND OPPORTUNITIES IN VALUE ASSESSMENT OF INNOVATIVE BIOLOGIC MEDICINES
user-icon

Yasuko Aitoku

Bayer Yakuhin Ltd.

Head of Market Access

Osaka

Japan

W17: HOW E-CONNECTED MEDICINE WILL CHANGE THE VALUE OF PHARMACEUTICALS
Manabu_Akazawa

Manabu Akazawa

Public Health and Epidemiology Department, Meiji Pharmaceutical University

Professor

Tokyo

Japan

Health Economics, Health Technology Assessment, Methods, Outcome Assessment, Policy, Real World Data Real World Evidence in Asia-Pacific: Are We Ready? Is It Helpful for Decision Makers?
user-icon

Junya Ako

Kitasato University

Professor and Chairman

Sagamihara

Japan

EDUCATIONAL SYMPOSIUM: CHALLENGES AND OPPORTUNITIES IN VALUE ASSESSMENT OF INNOVATIVE BIOLOGIC MEDICINES
Bart_Barefoot

Bart Barefoot

Real World Evidence Policy and Advocacy, Value Evidence and Outcomes (VEO), Global Medical, GlaxoSmithKline

Director & VEO

London

United Kingdom

Health Technology Assessment, PROs & Patient Engagement, Policy, Real World Data, Value Assessment Frameworks Real World Evidence in Asia-Pacific: Are We Ready? Is It Helpful for Decision Makers?
0

Klair Bayley, Bsc RM RN

Save Our Sons Duchenne Foundation

Executive Office - Clinical Care and Advocacy

Hurlstone Park

Australia

Health Economics, Modeling, Outcome Assessment, Patient Engagement, Patient Preference & Adherence, Policy, Real World Data, Regional Or Country, Specific Disease Or Drug Areas, Value Assessment Frameworks IP17: HOW COLLABORATIVE CAN COMPANIES BE IN DEVELOPING EVIDENCE TO SUPPORT MARKET ACCESS?
user-icon

Yukti Bhargava

Roche Singapore Pte. Ltd.

Regional HTA and Pricing Lead, APAC

Singapore

Singapore

-
Pic

Dr Devarshi Bhattacharyya, BDS, MSc, MPH

Kalam Institute of Health Technology (KIHT)

Assistant Director

Visakhapatnam

India

Health Economics, Health Technology Assessment, Medical Devices & Diagnostics, Modeling F2: HEALTH TECHNOLOGY ASSESSMENT OF MEDICAL DEVICES IN ASIA PACIFIC
Bolt_Tim ISPOR

Timothy Bolt

Saitama University

Associate Professor

Saitama

Japan

Health Economics, Health Technology Assessment, Methods, Patient Preference & Adherence, Policy IP20: DISCRETE CHOICE EXPERIMENTS AS A MEASURE OF SOCIAL VALUE AND PREFERENCES: APPLICATION TO POLICY MAKING IN ASIA-PACIFIC
Brixner_Diana

Diana Brixner, PhD, RPh, FAMCP

University of Utah, College of Pharmacy

Professor

Salt Lake City

United States

Clinical Outcomes, Economic Outcomes, Outcomes Research Methods, Patient-Centered Outcomes, Use Of Outcomes Research In Decisions EDUCATIONAL SYMPOSIUM: VALUE-BASED DECISION MAKING IN DEVELOPING COUNTRIES: MULTI-CRITERIA DECISION ANALYSIS (MCDA) FOR OFF-PATENT PHARMACEUTICALS, W16: THE APPLICATION OF INDICATION BASED PRICING TO REGENERATIVE MEDICINE THERAPIES: AN INTERACTIVE WORKSHOP
Icon

Thomas Butt, PhD

Peking University

Research Fellow

Beijing

China

IP7: WHAT IS THE VALUE OF RARE DISEASE THERAPIES FOR DEVELOPING HEALTHCARE SYSTEMS?, IP16: DOES TRANSPARENCY HELP OR HINDER EMERGING HTA SYSTEMS?
user-icon

Joshua Byrnes

Griffith University

Associate Professor

Brisbane

Australia

IP14: MANAGED ENTRY SCHEMES: HYPE VS. REALITY
user-icon

Joe Caputo

Vista Health Pte Ltd.

Managing Director

Singapore

Singapore

IP18: HOW TO DEAL WITH MODEL UNCERTAINTY AT THE PLANNING STAGE OF COST-EFFECTIVENESS ANALYSIS?: TIPS FROM GLOBAL EXPERIENCES
Caro_Jaime-picture

J. Jaime Caro, MDCM

Evidera, Waltham, MA, USA and Adjunct Professor of Medicine, Adjunct Professor of Epidemiology and Biostatistics

Chief Scientist

Montreal

Canada

Health Economics, Health Technology Assessment, Medical Devices & Diagnostics, Methods, Modeling, Outcome Assessment, Patient Engagement, Patient Preference & Adherence, Policy, Pricing-Access-Risk Sharing, Real World Data, Regional Or Country, Specific Disease Or Drug Areas, Studies, Value Assessment Frameworks IP5: BETTER THE DEVIL YOU KNOW? QALYs AND THEIR ALTERNATIVES IN DRUG REIMBURSEMENT DECISION-MAKING, W6: RESPONSE BASED COST-EFFECTIVENESS MODELING IN IMMUNO-ONCOLOGY
K'Nui

Professor Nathorn Chaiyakunapruk

Naresuan University

Professor of Health Economics

Phitsanulok

Thailand

Health Economics, Health Technology Assessment, Medical Devices & Diagnostics, Methods, Modeling, Outcome Assessment, Patient Preference & Adherence, Policy, Pricing-Access-Risk Sharing, Real World Data, Regional Or Country, Specific Disease Or Drug Areas, Studies, Value Assessment Frameworks W1: HEALTH ECONOMIC EVALUATIONS TO SUPPORT PUBLIC HEALTH DECISION-MAKING IN VACCINES: ARE COST-EFFECTIVENESS ANALYSIS AND BUDGET IMPACT ANALYSIS SUFFICIENT TO ANSWER THE POLICY QUESTIONS?, IP15: CURRENT PRACTICES AND PROSPECTS IN MANAGING REIMBURSEMENT IN ASIA PACIFIC AND EUROPE: WHAT WE CAN DO MORE TO BRIDGE THE EXPERIENCE AND EXPECTATION?
Chaiyakunapruk_Nathorn

Nathorn Chaiyakunapruk, PharmD, PhD

Monash University

Professor

Petaling Jaya

Malaysia

Network Meta-Analysis and Indirect Treatment Comparisons
Arnold_Chan

K. Arnold Chan

Health Data Research Center, National Taiwan University, Director, Department of Medical Research, and Director, Clinical Trial Center, National Taiwan University Hospital

Director

Taipei

Taiwan

Introduction to Real World Data and Informatics in Health Care, Real World Evidence in Asia-Pacific: Are We Ready? Is It Helpful for Decision Makers?